Confidence bands for the difference of two s rvival c rves nder proportional hazards model

Mei-Jie Zhang, Ph.D. John P. Klein, Ph.D.

Technical Report 29

February 1998

Division of Biostatistics Medical College of Wisconsin 8701 Watertown Plank Road Milwaukee WI 53226 Phone: (414)456-8280

CONFIDENCE BANDS FO THE DIFFE ENCE OF TWO SU VIVAL CU VES UNDE P OPO TIONAL HA A DS MODEL

Mei-Jie Zhang and John P. Klein

Medica Go ege of Wisconsin

A stract.

A common approach to testing for differences between the survival rates of two therapies is to use a proportional hazards regression model which allows for an adjustment of the two survival functions for any imbalance in prognostic factors in the comparison. An alternative approach to this problem is to plot the difference between the two predicted survival functions with a confidence band that provides information about when these two treatments differ. Such a band will depend on the covariate values of a given patient. In this paper we show how to construct a confidence band for the difference of two survival functions based on the proportional hazards model. A simulation approach is used to generate the bands. This approach is used to compare the survival probabilities of chemotherapy and allogeneic bone marrow transplants for chronic leukemia.

1. Introduction

A common problem encountered in biomedical applications is the comparison of the survival rates of two treatments. In this comparison one tests whether the two treatments have the same survival function or equivalently the same hazard function over a given time period. When there are additional covariates associated with survival then this testing is typically performed in the framework of a ox (1972) proportional hazards model.

When the testing results indicate that two survival functions are different, patients and physicians often want to known "at what times are these two treatments different?". This is ph (neurophysicate) (1999) (19

plots and comparing the confidence bands with the zero line summarizes how the difference between the two survival functions change with time. Recently, Parzen *et a* (1997) used the Kaplan-Meier (1958) estimators of the two survival functions, $\hat{F}_1(\cdot)$ and $\hat{F}_2(\cdot)$, to estimate the difference between the survival functions and they proposed a simulation method to construct a confidence band for this difference.

In many applications there is a need, when comparing two treatments, to make adjust-

Hara, β can be astimated by maximizing the stratified ox partial log likelihood function

$$C(\beta,t) = \sum_{i=1}^{2} \sum_{j=1}^{n_i} \int_0^t \beta' Z_{ij} d_{-ij}(u) - \sum_{i=1}^{2} \int_0^t \log\left(\sum_{j=1}^{n_i} Y_{ij}(u) e^{\beta' Z_{ij}}\right) d_{-i}(u),$$

where $_{ij}(u) = I\{X_{ij} \leq T_{ij} \leq u, D_{ij} = 1\}$, $\bar{i} = \sum_{i} _{ij}$, and $Y_{ij}(u) = I\{X_{ij} \leq u \leq T_{ij}\}$ is the indicator of whether the *j*th individual is at risk at time *u* and is in the *i*th treatment group. Note that an individual is at risk only since his or her truncation time, so that the size of the risk set is initially increasing and then decreases.

To compara two pradictad survival curvas, wa astimata that conditional survival functions for the two tratmants for a patient with a particular set of covariates z_0 ,

$$F_i(t;z_0) = P(T > t | z_0, \text{ Treatment } i) = e^{-\Lambda_i(t;z_0)},$$

whara $\Lambda_i(t|z_0) = e^{\beta' z_0} \int_0^t \lambda_{i0}(u) du$. An astimator of the cumulative baseline hazard rate for treatment i, i = 1, 2 is given by Breslow's (1975) estimator

$$\hat{\Lambda}_{i0}(t) = \int_0^t \frac{d^{-}_{i}(u)}{\sum_{j=1}^{n_i} Y_{ij}(u) \exp(\hat{\beta}' Z_{ij})}.$$

For convaniance we introduce the notations

$$\begin{split} S_{i}^{(k)}(\beta,t) &= \frac{1}{n_{i}} \sum_{j=1}^{n_{i}} Y_{ij}(t) Z_{ij}^{\otimes k} e^{\beta' Z_{ij}}, \\ E_{i}(\beta,t) &= S_{i}^{(1)}(\beta,t) / S_{i}^{(0)}(\beta,t), \\ V_{i}(\beta,t) &= S_{i}^{(2)}(\beta,t) / S_{i}^{(0)}(\beta,t) - E_{i}(\beta,t) \\ s_{i}^{(k)}(\beta,t) &= E\{S_{i}^{(k)}(\beta,t)\}, \\ e_{i}(\beta,t) &= s_{i}^{(1)}(\beta,t) / s_{i}^{(0)}(\beta,t), \\ v_{i}(\beta,t) &= s_{i}^{(2)}(\beta,t) / s_{i}^{(0)}(\beta,t) - e_{i}(\beta,t), \end{split}$$

for i = 1, 2, and k = Q, 1, 2, where for a column vector $a, a^{\otimes 0} = 1, a^{\otimes 1} = a$, and $a^{\otimes 2} = aa'$.

For simplicity of presentation, we assume $\{X_{ij}, T_{ij}, D_{ij}, Z_{ij}\}$, $(j = 1, \dots, n_i)$ are independent and identically distributed, $P(T_{ij} \ge X_{ij}) > 0$, and $\{Z_{ij}\}$ is bounded. Left-truncated and right-censored survival data has been studied extensively. The more general conditions required to obtain large sample results for this type of data can be found in Woodroofe (1985), Lai and Ying (1991) and Andersen *et a* (1993). Andersen *et a* (1993) argued that the martingale central limit theory can be applied to the left-truncated data, so that the asymptotic results based on right censored data can be extended to the left-truncated and right censored data. Also we assume that two samples are independent. Let $n = n_1 + n_2$. Then, if $n_i/n \longrightarrow p_i > 0$, for i = 1, 2, $\hat{\beta}$ is an consistent estimate of β , and

$$\sqrt{n}(\hat{\beta} - \beta) \xrightarrow{\mathcal{D}} (0, \Sigma^{-1})$$

whare

$$\Sigma = \sum_{i=1}^{2} p_i \int_0^\infty v_i(\beta, t) s^{(0)}(\beta, t) \lambda_{i0}(t) dt,$$

which is assumed to be positive definite and can be consistently estimated by the observed information matrix 1

$$\widehat{\Sigma} = \int$$

It follows that the variance of $W(t;z_0$

The transplant cohort included 548 patients receiving hydroxyurea or interferon pretreatment and a HLA-identical sibling bone marrow transplant (BMT). All patients were reported to the International Bone Marrow Transplant Registry (IBMTR). IBMTR is a voluntary working group of over 300 transplant centers worldwide that contribute data on their allogenetic bone marrow transplants to a Statistical enter at the Medical ollege of Wisconsin. Patients in this arm were diagnosed between 1983 and 1991, and were between 15 and 55 years of age. For detailed patient characteristics see Gale *et a* c3

 $t^{\rm hat}$

Figura 1a shows that astimated survival curves for a recently diagnosed (≥ 1988) older (≥ 35 years) male patient with large splean size ≥ 10 cm. Figure 1b shows the estimated difference (BMT- hermotherapy) between the two survival curves with a 95% pointwise confidence interval and 95% confidence band for such a patient. A similar plot for a patient diagnosed prior to 1988 with the same characteristics is given in Figure 2.

These confidence band plots indicated that the chemotherapy treatment has an early survival advantage due, perhaps, to the toxicity of the bone marrow transplant. There is a significant late survival advantage for transplant patient due to a lower relapse rate. Also for the recently treated cases (Figure 1) BMT had a survival advantage (95% confidence band is > Q) starting at 5.5Q years after diagnosis. This is in contrast to patients treated prior to 1988 (Figure 2) where BMT started to show an advantage only after 8.29 years since diagnosis. This may be due to the improvement of bone marrow transplant techniques over the years.

In this example, there are 16 sets of possible covariates values. The time points since diagnosis where BMT starts to heave a survival advantage are presented in Table 2. There time points ranged from 5.50 years to 8.29 years since diagnosis depending on the given patient characteristics. By contrast to the comparison of two Kaplan-Meier survival curves, this comparison of two predicted survival curves based on the ox model provides more information to both the physicians and patients.

ovariat# Valu#s					
Sax	Splæen Sizæ	Aga	Yaar of DX	C_{α}	t_0
М	< 10 cm	< 35	< 88	2.96	7.84
М	< 10 cm	< 35	≥ 88	2.97	5.97
М	$\geq 10 \text{ cm}$	< 35	< 88	2.96	7.84
М	$\geq 10 \text{ cm}$	< 35	≥ 88	2.99	5.88
М	< 10 cm	≥ 35	< 88	2.99	7.84
М	< 10 cm	≥ 35	≥ 88	2.95	5.88
М	$\geq 10 \text{ cm}$	≥ 35	< 88	2.96	8.29
М	$\geq 10 \text{ cm}$	≥ 35	≥ 88	2.94	5.50
F	< 10 cm	< 35	< 88	2.96	8.29
F	< 10 cm	< 35	≥ 88	2.93	5.97
F	≥ 10 cm	< 35	< 88	2.99	7.84
F	$\geq 10 \text{ cm}$	< 35	≥ 88	2.98	6.24
F	< 10 cm	≥ 35	< 88	2.92	7.84
F	< 10 cm	≥ 35	≥ 88	2.89	5.97
F	≥ 10 cm	≥ 35	< 88	2.90	7.84
F	$\geq 10 \text{ cm}$	≥ 35	≥ 88	2.92	5.88

Table 2. Time points t_0 since diagnosis (DX) in years where BMT starts to have survival advantage.

. emar s

Plotting the confidence band for the difference of two predicted survival functions provides a valuable decision making tool for physicians and patients. The proposed simulation method is easy to program, and offers a flexible way to construct such confidence bands, particularly when the limiting distributions cannot be evaluated analytically. The proposed simulation method can be extended to compare the difference of two survival curves based on other models, such as Aalen's (1989) additive model or other more general models.

The estimated critical value, C_{α} , depends on the number of realizations . It is important to know what is the appropriate . In our example for an early diagnosed young (< 35 yr) male patient with small spleen size (< 10 cm), the estimated C'_{α} s were 3.01, 2.98, 2.97, 3.01, 2.97, and 3.01 for = 500, 1500, 3000, 5000, 8000 and 10000, respectively. It appears that the estimate of C_{α} is resonably stable after only 500 replications.

Acknowledgments

This research was supported by Grant 2 RO1 A547Q6-Q6 from the National ancer Institute, and PO1- A-4QQ53 from the National ancer Institute, the National Institute of Allergy and Infectious Diseases and The National Heart, Lung and Blood Institute. We avaid the National Heart, State and Blood Institute.



